Bristol-Myers Squibb Aktie News

Subscribers to  Chart of the Week  received this commentary on Sunday, Dec, 28.

Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs.

Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status.

Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight loss drugs.

At the current price, investors are paying little for Bristol Myers' pipeline.

Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite cost-saving initiatives and the Hess acquisition, leading to subdued dividend growth. Dividend increases in January will generally be modest, with select companies like Fastenal, S&P Global, and C...

This drug company offers a decent balance of risk and reward, with a 4.6% yield and a payout ratio comfortably below 100%. This medical device company has a 2.9% yield and is nearing Dividend King status.

BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 56.5% of revenues, temporarily offsetting legacy declines while lending credibility to the thrice raised FY2025 guidance. Otherwise, BMY faces numerous Patent cliffs for Opdivo/Eliquis and the Medic...